In one of the most comprehensive genomic investigations of its kind, researchers in China have delivered a sweeping portrait of myelodysplastic neoplasms (MDS) driven by mutations in TP53, the gene famously dubbed the “guardian of the genome.” The retrospective study, published in Cancer Reports, analyzed next-generation sequencing data from 1,589 adults newly diagnosed with MDS at a single major hospital center and identified 161 patients carrying TP53 mutations—a prevalence of just over 10 percent that underscores both the rarity and the clinical gravity of this molecular subtype. The findings arrive at a pivotal moment, as the 2022 revisions of the World Health Organization’s fifth edition (WHO-5) and the International Consensus Classification (ICC) have formally recognized TP53-mutated MDS as a distinct diagnostic entity, demanding a more precise, genetics-driven approach to classification and treatment.

MDS itself is a notoriously heterogeneous group of clonal blood disorders in which the bone marrow fails to produce healthy blood cells effectively, a process known as ineffective hematopoiesis. Patients typically present with cytopenias—deficiencies in red cells, white cells, or platelets—and face a heightened risk of progression to acute myeloid leukemia (AML), one of the most aggressive hematological malignancies. Within this spectrum, TP53 mutations have long been recognized as harbingers of poor outcomes, frequently accompanying complex chromosomal abnormalities and conferring resistance to standard therapies. What has been missing, the authors argue, is a detailed accounting of exactly which kinds of TP53 mutations occur in Asian patients, how they cluster with other genetic lesions, and how their abundance within tumor cells correlates with measurable disease severity.

The p53 protein is a molecular linchpin of cellular integrity. Structurally, it comprises two transcriptional activation domains (TAD1 and TAD2), a proline-rich region, a central DNA-binding domain (DBD), a tetramerization domain, and a negative regulatory domain. When DNA damage strikes, p53 halts the cell cycle to permit repair or, if the damage is irreparable, triggers apoptosis. Mutations that disable this machinery remove a critical safeguard against malignant transformation. The new study confirms that in MDS, these mutational events concentrate overwhelmingly in the DNA-binding domain, with missense mutations—single DNA letter changes that substitute one amino acid for another—accounting for a striking 76.9 percent of all TP53 alterations detected. Nonsense mutations, which introduce premature stop signals that truncate the protein, were less common. This pattern is consistent with the biology of a tumor suppressor: rather than being eliminated outright, p53 is often sabotaged by subtle changes that leave a malformed but partially functional protein, sometimes with dominant-negative effects that poison the residual wild-type copies.

Perhaps the most clinically consequential finding involves variant allele frequency, or VAF—a measure of the proportion of sequencing reads carrying the mutant allele, which serves as a proxy for the fraction of cells in the tumor clone harboring the mutation. The researchers found that TP53 VAF correlated strongly with a battery of disease severity parameters: lower hemoglobin levels (reflecting worse anemia), higher bone marrow blast percentages (a marker of disease progression), adverse karyotype features, and higher risk scores across all three major prognostic frameworks in current use—the International Prognostic Scoring System (IPSS), the revised IPSS-R, and the newer IPSS-Molecular (IPSS-M), which incorporates genetic mutations into risk calculation. All correlations reached statistical significance. In practical terms, the more dominant the mutant TP53 clone within the marrow, the more aggressive the disease—a dose-response relationship that previous European and American cohorts had hinted at but that had never been so thoroughly quantified in an Asian population.

The study’s methodology reflects the sophistication of modern hematological genomics. Bone marrow DNA was extracted at diagnosis, and saliva samples were used to establish each patient’s germline profile, allowing the team to reliably distinguish inherited variants from somatic, tumor-acquired mutations—a critical quality-control step that many large-scale sequencing efforts omit. Sequencing employed a targeted 96-gene panel run on an Illumina NovaSeq platform, with stringent bioinformatic filtering: an average effective sequencing depth of at least 800× per sample, mapping and base quality scores of at least 30, and a minimum VAF threshold of 1 percent for single nucleotide variants and small insertions or deletions. Reads were aligned to the human genome (hg19) using the Burrows-Wheeler Alignment tool, processed through the Genome Analysis Toolkit pipeline for recalibration and realignment, and variant calling was performed with Mutect2 before annotation through ANNOVAR, drawing on databases including COSMIC, 1000 Genomes, SIFT, and PolyPhen.

Beyond TP53 itself, the sequencing data revealed a rich landscape of co-occurring mutations that appear to shape the clinical behavior of these cancers. Epigenetic regulators were the most frequent companions: DNMT3A, an enzyme central to DNA methylation, was mutated in 11.8 percent of patients; TET2, another methylation pathway gene, in 10.6 percent; and ASXL1, a chromatin remodeling regulator, in 9.3 percent. These partnerships matter because they alter disease phenotype in mechanistically intelligible ways—disrupted methylation patterns and impaired chromatin architecture can lock hematopoietic stem cells into aberrant differentiation states, while mutations in splicing factors such as SF3B1 and U2AF1, also observed in MDS more broadly, corrupt RNA processing. As prior work by Symes and colleagues has emphasized, these co-mutations are not passive passengers; they actively modify how TP53-mutated disease unfolds, and disentangling their contributions remains one of the field’s most pressing open questions.

The prognostic stakes of TP53 status are difficult to overstate. Citing a landmark analysis of 3,148 MDS patients by Bernard and colleagues, the authors note that median overall survival falls to a mere 8.7 months in patients with multi-hit TP53 states—defined as two or more distinct TP53 mutations, a single mutation accompanied by loss of heterozygosity on chromosome 17p, or frank deletion of the short arm of chromosome 17. By contrast, patients with a single (mono-allelic) TP53 mutation survive a median of 2.5 years, and those with wild-type TP53 fare substantially better at 3.5 years. Earlier studies have proposed varying VAF thresholds—≥20 percent in analyses by Montalban-Bravo and Montoro, and ≥22 percent by Tefferi and colleagues—beyond which outcomes deteriorate markedly, reinforcing the idea that mutant clone size is itself a prognostic variable. The new Chinese cohort’s confirmation that VAF tracks with IPSS-family risk categories lends further weight to the case for incorporating quantitative TP53 metrics into routine diagnostic workflows.

Therapeutically, the implications are equally significant. Standard care for MDS relies heavily on hypomethylating agents and supportive transfusions, but TP53-mutated disease notoriously defies these approaches, and allogeneic hematopoietic stem cell transplantation—the only potentially curative option—still yields generally poor survival in this subgroup. That therapeutic vacuum has fueled intense interest in agents designed to target mutant p53 directly, most prominently eprenetapopt (APR-246), a small molecule that appears to restore apoptotic function to certain mutant p53 conformers and that remains under active clinical investigation. Precise risk stratification, the authors argue, is a prerequisite both for identifying which patients stand to benefit from such targeted therapies and for meaningfully interpreting the clinical trials that will determine their fate. A validated picture of the TP53-mutated landscape in Asian populations, where such data have been conspicuously scarce, is an essential piece of that foundation.

The study, conducted at the First Affiliated Hospital of Zhejiang University School of Medicine between July 2021 and December 2024, enrolled all consecutively diagnosed adults meeting WHO-5 criteria for MDS who had baseline bone marrow sequencing available and at least one TP53 mutation detected by next-generation sequencing. Statistical analyses, performed in SPSS and R, compared continuous variables across patient subgroups using non-parametric tests and assessed categorical differences with chi-square or Fisher’s exact methods, with clinical cut-offs drawn from established IPSS and IPSS-R criteria. While the retrospective, single-center design and modest subgroup sizes counsel caution in generalizing the findings, the cohort’s size—161 mutation carriers within nearly 1,600 consecutively sequenced patients—makes it among the largest Asian TP53-focused MDS datasets published to date.

As precision oncology matures, the message from Hangzhou is clear: in TP53-mutated MDS, the details matter. Which domain of p53 is mutated, how many hits the gene has sustained, how abundant the mutant clone is, and which epigenetic co-conspirators share the cellular stage—all of these variables now demonstrably shape prognosis and therapeutic opportunity. With international classification systems already pivoting toward multi-hit TP53 definitions, and VAF emerging as a quantitative prognostic compass, studies like this one are helping to convert a once uniformly bleak diagnosis into a molecularly stratified disease in which the right patients can, at last, be matched to the right trials and the right drugs.

Subject of Research: People

Subject of Research: Cancer

Article Title: Genetic and Clinical Features in TP53-Mutated Patients With Myelodysplastic Neoplasms: A Retrospective Study Based on Next-Generation Sequencing Data

Article References: Cheng, Y., Liu, L., Gao, Y., Wang, Y., Zhu, W., Chen, H., Qin, J., & Zhang, Y. (2026). Genetic and Clinical Features in TP53 ‐Mutated Patients With Myelodysplastic Neoplasms: A Retrospective Study Based on Next‐Generation Sequencing Data. Cancer Reports, 9(6), Article e70584. https://doi.org/10.1002/cnr2.70584

Image Credits: AI Generated

DOI: 10.1002/cnr2.70584

Keywords: TP53, myelodysplastic neoplasms, variant allele frequency, next-generation sequencing, IPSS-M, DNMT3A, TET2, ASXL1

Cite Scienmag News
APA MLA Chicago

Juliet Wilcox. (September 8, 2026). Study reveals genetic and clinical features of TP53-mutated myelodysplastic neoplasms. Scienmag. https://scienmag.com/study-reveals-genetic-and-clinical-features-of-tp53-mutated-myelodysplastic-neoplasms/

Copy citation Download RIS

Tags: clinical features of TP53 in MDSclinical features of TP53 mutations in MDSgenetic mutations in myelodysplastic syndromesgenetic profiling in myelodysplastic syndromesgenomic profiling of clonal blood disordersgenomics of myelodysplastic syndromeshematopoiesis and clonal blood disordershematopoiesis and cytopenias in MDSmolecular classification of MDSmolecular subtypes of myelodysplastic syndromesnext-generation sequencing in hematologic malignanciesnext-generation sequencing in hematological malignanciesprognostic significance of TP53 mutationsrisk factors for progression to AMLrisk of progression to acute myeloid leukemiatargeted therapy approaches for TP53-muttargeted treatmentTP53 mutation prevalence and prognosisTP53-mutated myelodysplastic neoplasmsWHO-5 and ICC classification of MDSWHO-5 and ICC classification updates for MDS